Responsible decision-making in pharmaceutical manufacturing increasingly occurs within complex, distributed, and rapidly evolving environments. While the European Qualified Person (QP) holds defined regulatory accountability, modern decision contexts extend beyond compliance verification and require integration of scientific understanding, life cycle knowledge, and organizational governance. Building on recent discussions surrounding technological evolution and regulatory expectations, this review explores how professional judgment operates in environments characterized by uncertainty, accelerating timelines, and expanding organizational interfaces. Specification compliance alone often provides insufficient confidence for decision-making. Confidence increasingly emerges through process understanding, integration of multidisciplinary expertise, and development of coherent scientific interpretation connecting data, process behavior, and patient expectations. Accelerated environments also reveal how governance structures and organizational systems influence decision quality, highlighting the importance of clear accountability, trusted expertise, and independent judgment. This paper introduces the concept of patient-relevant decision quality and discusses how experienced professionals contribute to the continuity of understanding across life cycle stages. Although advanced analytical tools and emerging digital capabilities increasingly support process interpretation and decision-making, responsible decisions within GMP environments remain anchored in professional judgment, organizational governance, and regulatory accountability. Seen through this lens, the QP represents one perspective within a broader system of responsible decision-making in which organizational maturity, principled leadership, and stewardship of judgment support scientifically grounded and ethically sound outcomes.
For the first time in its history, the U.S. Food and Drug Administration (FDA) announced a landmark policy shift aimed at increasing transparency by publicly releasing Complete Response Letters (CRLs) in near real-time, even for applications that are pending, withdrawn, or abandoned. This bold step transforms regulatory transparency and shifts the balance between sponsors, regulators, and the public.The new policy has immediate and far-reaching consequences. For the industry, public disclosure of CRLs will reshape how sponsors approach development planning, regulatory submissions, and external communications. The availability of detailed deficiency letters will allow competitors and new entrants to learn from regulatory precedent, potentially improving submission quality and reducing duplicative errors. At the same time, greater transparency raises essential questions regarding intellectual property protection, reputational risk, and alignment of corporate disclosures with the FDA's regulatory record.For stakeholders-including drug developers, investors, and regulators-this new framework introduces both opportunities and challenges. It promises to enhance regulatory predictability and public trust, while requiring careful recalibration of confidentiality practices and regulatory risk management strategies. This poster will analyze the policy in detail, highlight anticipated impacts on development programs and communication strategies, and discuss the broader implications for regulatory science and industry practice.
Maintaining microbial control in pharmaceutical manufacturing environments is a cornerstone of Good Manufacturing Practices (GMP). This comprehensive review outlines the development, validation, and implementation of robust cleaning and disinfection programs for pharmaceutical facilities, including cleanrooms, Restricted Access Barrier Systems (RABS), and isolators. The article integrates regulatory expectations from U.S. FDA (21 CFR 211), EU GMP Annex 1, and industry guidance documents such as USP <1072>, PDA TR70, and IEST RP 18.5, emphasizing the importance of both laboratory-based disinfectant efficacy studies and in situ field trials. Key topics include the selection and rotation of disinfectants and sporicidal agents, validation methodologies, environmental monitoring strategies, and the role of Vaporized Hydrogen Peroxide (VHP) in bio-decontamination. Case studies and data-driven insights illustrate best practices for ensuring contamination control, including equipment cleaning validation and requalification protocols. The article advocates for a sound approach to validate both manual and automated disinfection technologies, offering a forward-looking perspective on contamination control in modern pharmaceutical manufacturing.
The increasing evaluation and adoption of Biofluorescent Particle Counters (BFPCs) for Grade A environments have introduced instruments that operate at lower flow rates, such as 5 L/min, to simultaneously count both viable and total particles. This flow rate differs from the conventional 28.3 L/min referenced in the current EU GMP Annex 1 for total particle counting. The divergence is motivated by the higher effectiveness of viable particle detection achieved with a lower flow rate and by the suppression of a virtual impactor and its associated particle losses.The study provides supportive information for justifying a lower flow rate when sampling in Grade A environments with homogeneous, unidirectional airflow. The performance of two commercially available particle counters was compared to assess whether the lower flow rate is non-inferior in detecting deviations of environmental quality for both 0.5 μm and 5 μm total particles: one operating at the standard flow rate of 28.3 L/min (1 ft3/min) and the other at 2.83 L/min (0.1 ft3/min), representing a proportional flow rate relative to a 5 L/min Biofluorescent Particle Counter.Two distinct experimental setups representing Grade A environments were used: a laboratory-scale microbiological biosafety cabinet (BSC) featuring homogeneous unidirectional airflow at 0.45 m/s, and a custom-built room-sized Grade A chamber equipped with an integrated air purification system and controlled ventilation to simulate full-scale cleanroom conditions. Both setups exposed the particle counters to identical contamination events generated by external ventilators to evaluate performance across different spatial scales and airflow dynamics while maintaining Grade A compliance.The alert thresholds of the two standard particle counters deployed in this study showed a high level of concordance under unidirectional airflow. No consistent preference was observed for one counter over the other in terms of alert precedence. In the BSC setup, the lag time between the two instruments was limited to 1 minute in 96% of cases. Collectively, data from both experimental setups were strongly supportive to demonstrate that operating a particle counter at a lower flow rate is non-inferior to the standard flow rate, maintains equivalent environmental control, and underlines its suitability for application in Grade A zones.
This study investigates the dynamics of break loose glide force (BLGF) in prefilled syringes (PFS) and injection time in autoinjectors (AI) across different orientations and time points, focusing on their impact on drug delivery performance. PFS and Autoinjectors are pivotal in modern therapeutics, enabling precise administration of biologics, vaccines, and other sensitive pharmaceuticals. Patients with chronic conditions and individuals with limited dexterity requiring frequent self-administration, all benefit from devices that minimize BLGF to ensure consistent injection times. To explore the influence of storage orientation (tip-up vs. tip-down) and time on these devices, we conducted a comprehensive evaluation over a 12-month period supplemented by reference timepoint samples. Utilizing a dual-orientational framework, PFS and autoinjectors were stored under controlled conditions to assess orientation-dependent performance. Aged and empty samples served as reference controls. The study's primary metrics included BLGF, which is the initial force required to initiate plunger movement then enable injection along the barrel, and injection time. These parameters were analyzed using a calibrated Zwick/Roell mechanical tester under controlled environmental conditions.Key findings reveal statistically significant but not practically impactful effects of storage orientation on BLGF or injection time across all tested intervals. Minor time-based variations were noted, with BLGF shifts being less than 1 N and injection time deviations under 2 seconds. These changes indicated no practical significance or risk of out-of-specification performance. The Analysis of variance (ANOVA) analysis confirmed no evidence suggesting orientation affects functionality.This work demonstrates that short to mid-term storage conditions do not adversely affect device performance, providing critical assurance for manufacturers, regulators, and end-users. The study highlights the robustness of PFS and Autoinjectors against orientation and temporal changes, mitigating risks associated with handling variability and optimizing supply chain logistics. Future research should extend these findings to longer durations to confirm long-term stability.
Misconceptions and misleading claims about VH2O2/VHP sterilization and bio-decontamination are increasingly common in today's market. For pharmaceutical and medical device manufacturers, understanding the key differences between the two VH2O2 application methods is essential for successful implementation and regulatory compliance.VH2O2 technologies have been in continuously increasing role for ensuring proper risk assessment and contamination control in pharmaceutical manufacturing processes, especially highlighted by the 2022 revision of EU Annex 1. VHP is specifically important for sensitive drug products manufacturing such as aseptic processing, cleanroom bioburden control and low-temperature terminal surface sterilization of prefilled syringe and other combination products.This presentation will discuss the following topics: Process and technology, applications, pros and cons, implementation, testing and validation of VH2O2 processesRecent regulatory developments for VH2O2 technologiesCommon denominators and differences between VH2O2 sterilization and bio-decontaminationDebunking misconceptions and misleading claimsFuture of VH2O2 technologies in the pharmaceutical and medical device industry.
Castanopsis sieboldii is a phenolic-rich evergreen species in the family Fagaceae, yet comprehensive quantitative and tissue-specific metabolite profiling remains limited. In this study, an integrated analytical workflow comprising UHPLC-PDA quantification, LC-QToF-MS identification, and chemometric analysis was developed to characterize phenolic constituents in leaves, flowers, fruits, and stems. A validated UHPLC-PDA method enabled the simultaneous quantification of six major phenolics, with limits of detection ranging from 0.01 to 0.05 μg/mL and limits of quantification from 0.025 to 0.1 μg/mL. Among all tissues, 3‑O‑galloylshikimic acid (Compound 1) was the predominant metabolite (0.1-204 mg/g), followed by caffeoylquinic acids (Compounds 2-3), ellagic acid (Compound 4), and flavonoid glycosides (Compounds 5-6). LC-QToF-MS analysis facilitated the tentative annotation of 185 metabolites, including phenolic acids, ellagitannins, galloylshikimic acids, and flavonoid glycosides, based on accurate mass measurements and characteristic MS/MS fragmentation patterns. Chemometric evaluation using principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and hierarchical clustering analysis (HCA) revealed clear tissue-specific clustering, with leaves exhibiting the highest chemical diversity and phenolic abundance, whereas fruits showed minimal levels. PCA captured 80% of total variance in the first two components, and the PLS-DA model showed strong predictive performance (R²Y ≈ 1.00; Q² ≈ 0.98) although interpretation should consider the limited sample size. This study provides a comprehensive, tissue-resolved phenolic profile of C. sieboldii, establishing a robust chemical foundation for future pharmacological, ecological, and quality-control applications.
Pharmaceutical manufacturers are implementing BFPC technology for in-process monitoring and control of unidirectional air flow in aseptic filling operations to improve cleanroom operations, thus enhancing sterility assurance and product quality. Continuous real-time monitoring is able to reduce the industry's reliance of growth-based methods for 5 to 7-day incubation periods to obtain results. A similar approach to surface and personnel monitoring is necessary to complete the environmental monitoring review for GMP batch release without the delay due to the traditional methods.This poster will offer an overview of what the M3 collaboration expects the vendor community to include when developing instrumentation for BFPC surface monitoring as part of the User Requirement Specification (URS). Key elements include the rationale for development, device description, business case, validation and calibration parameters, and desirable features.A major consideration is the ability to count Auto-fluorescent Units (AFU) per 25 cm2 on both flat facility surfaces and irregular ones (for example, needles, stopper tracks, stopper insertion pistons). This may require two sampling devices rather than one. The aim of our initiative is to streamline the development of a BFPC surface monitoring system; feedback on the value of the proposed URS will be gathered during the poster session.
Aseptic processing remains one of the most challenging and closely scrutinized areas in pharmaceutical manufacturing. Using Redica Systems' global inspection and enforcement database spanning FDA, EMA/MHRA, and other PIC/S member agencies, this presentation analyzes compliance findings from 2022 to the present to highlight both persistent challenges and emerging risks in sterile manufacturing.Key themes include environmental monitoring and contamination control strategies, aseptic technique and human factors, sterilization validation, gowning and operator qualification, airflow visualization and smoke studies, and cleaning and disinfection effectiveness. We will also examine how regulatory expectations have shifted following the implementation of the revised EU GMP Annex 1, with particular attention to contamination control strategy and the adoption of barrier technologies.To illustrate these broader global trends, FDA enforcement serves as a case study. Sterility-related issues account for over 40% of production observations in 483s and over half of production deficiencies in Warning Letters. Inspections citing sterility issues were far more likely to escalate. Viewed alongside inspection findings from EMA and PIC/S agencies, these insights will give attendees a clear view of the compliance landscape and how global regulators are converging-or diverging-on expectations for sterile manufacturing.
Subcutaneous (SC) delivery of biologics is evolving to accommodate the greater volumes and doses required for efficacy. Conventional handheld auto-injectors are constrained by volume and speed limitations, prompting the development of high-volume auto-injectors (HVAIs) and wearable on-body injectors (OBI). A Near-Body Injector (NBI) system offers a novel approach by combining the benefits of high-volume delivery with hands-free operation, without the need for adhesive attachment associated with OBI's by using a standard winged infusion set and a mechanical priming mechanism incorporated into the device. This study evaluated the feasibility of a NBI system in a porcine model, delivering SC immunoglobulin alone and in combination with recombinant human hyaluronidase PH20 (rHuPH20), an enzyme known to enhance SC dispersion and absorption.Results demonstrated that the NBI system was easily primed and effectively delivered 10 mL SC. Co-formulation with rHuPH20 significantly improved injection performance, reducing delivery time by ∼13%, eliminating back-leakage, and decreasing swelling volume and induration at the injection site. These findings support the clinical potential of NBI systems for hands-free high-volume, high-dose biologic administration, offering an alternative to conventional SC delivery methods.
Ready-to-use (RTU) long-acting injectable aqueous suspensions offer sustained drug release but present significant challenges for terminal sterilization. While aseptic processing is frequently used for suspension manufacturing, it lacks the sterility assurance of terminal sterilization. This work investigated the viability of gamma sterilization of model RTU aqueous suspensions containing varying polymer types and suspended drug loads. Comprehensive physicochemical characterization revealed that gamma irradiation did not affect the drug solid-state form in both model suspensions, and effectively stabilized particle size, notably stopping particle size growth observed in the non-irradiated GSK model suspension (control group). However, size exclusion chromatography (SEC) and HPLC analyses confirmed significant radiolytic degradation of polymeric surfactants and stabilizers (poloxamer 338 and PEG 3350) in both naproxen and GSK model suspensions, characterized by random chain scission and cross-linking of the polymer chains. This polymer degradation induced by radiolysis resulted in a measurable reduction in viscosity and injection force, thereby easing the force required to push suspension through the narrow needle bore of the syringe. Conversely, radiolysis-induced loss of suspension microstructure compromised long-term physical stability (resuspendability), leading to irreversible caking after 18 months of storage. These findings indicate that while gamma irradiation is a plausible terminal sterilization method for injectable suspensions, careful consideration must be given to formulation design to compensate for radiolytic polymer degradation and maintain suspension physical stability over the desired shelf life.
Modern pharmaceutical manufacturing increasingly relies on high-frequency, high-dimensional and dynamically evolving data. Traditional statistical tools-such as univariate Statistical Process Control (SPC), Shewhart logic and Nelson's rules-remain valuable for routine monitoring, but are constrained by assumptions of independence, stationarity and linearity. These assumptions are frequently violated in contemporary bioprocesses, leading to inconsistent diagnostics and elevated false-alarm rates. Such limitations have been documented in data-rich manufacturing environments and confirmed in continued process verification initiatives, where repeated univariate rule violations were shown to lack biological relevance.In parallel, regulatory frameworks-including FDA Process Analytical Technology (PAT), ICH Quality by Design (QbD) and the draft EudraLex Annex 22 on Artificial Intelligence (AI)-increasingly emphasize scientifically justified, model-based approaches. This manuscript examines the boundaries of classical statistical methods, the inherently multivariate and dynamic nature of modern pharmaceutical processes, and the role of fixed deterministic and fixed probabilistic AI-based models in addressing analytical gaps. A structured scientific exploration framework is proposed to support evidence-based regulatory acceptance of advanced modelling approaches while improving process understanding, product quality and manufacturing efficiency.
The safety and quality of injectable drug products are influenced not only by formulation and manufacturing processes but also by the container closure system, including prefilled syringes and vials. Extractables and leachables (E&L) from elastomers, plastics, adhesives, and coatings can migrate into formulations, affecting safety, efficacy, and compliance. In parallel, residual process impurities may compromise stability during long-term storage. Emerging concerns highlight additional risks. Formation of nitrosamine compounds arising from drug-excipient or impurity interactions has raised global regulatory scrutiny due to their potential carcinogenicity. Likewise, siliconization of prefilled syringes while essential for functionality can alter glide forces and introduce silicone oil droplets, with implications for both product performance and patient safety. These evolving challenges underscore the importance of a holistic risk-based E&L framework.This presentation will discuss strategies aligned with USP < 1663>, < 1664>, ICH, and EMA guidance with emphasis on: Characterizing and monitoring E&L under stability conditionsEvaluating nitrosamine formation and syringe siliconization risksApplying robust analytical and mechanical testing methodologiesIntegrating findings into lifecycle and regulatory strategiesHolistic E&L evaluations incorporating chemical, mechanical, and toxicological perspectives strengthen product quality, patient safety, and regulatory confidence while supporting innovation in injectable drug delivery systems.
Enzyme Indicators (EIs) are strips of purified thermostable adenylate kinase (tAK) that are currently used across the world in the pharmaceutical industry to quantitatively assess the bio-decontamination efficacy of hydrogen peroxide (H2O2). Adoption of EIs in the hydrogen peroxide bio-decontamination cycle validation has increased across the pharmaceutical industry because of the numerous advantages they have over current assessment tools such as biological indicators (BIs). These benefits include a rapid result, reduced variation, and simplified handling due to the reduced contamination risk incurred from not using viable organisms. A number of pharmaceutical industry validation teams who have successfully integrated EI technology into their validation strategy realized that it would be advantageous to have an EI industry working group to look together at the adoption of the technology and bring a standardization of the validation approach. This paper provides a comprehensive approach to analyzing and applying EI use following the extensive compilation of data and methods from leading global pharmaceutical companies, including the points that are to be considered for handling, use, and data analysis of EIs within the steps of bio-decontamination validation.
Environmental monitoring is essential for the prevention and control of microbial contamination. Accurate and reproducible monitoring is critical, and standardized precise conditions of incubation in regulatory documents for environmental sampling are still lacking. This study investigated microbial recovery and growth dynamics under a controlled single-temperature incubation setting (25°C, 27.5°C and 30°C) across 83 microbial agents (49 bacteria, 24 molds and 10 yeast strains). We showed that at the temperature of 25°C, all microbial strains investigated were recovered. Elevated incubation temperatures did not alter the recovery of bacteria and yeast strains but affected the recovery and recovery rate of specific mold strains. In addition, time-to-result (TTR), defined as the time necessary for 90% colony recovery, varied with incubation temperatures and microbiota. It decreased with increasing temperature for all bacterial strains tested, while showing more complex patterns for molds. Altogether, our results contribute valuable insights into microbial ecology and highlight the complex interaction between temperature and microbial behavior. This study emphasizes the necessity for precise temperature regulation in microbial culture methodologies for accurate and reproducible environmental monitoring.
Customer complaints due to drug product abnormalities may arise even with strict quality control measures at the manufacturing and healthcare provider levels, posing serious challenges for the manufacturers. In this paper, we report three compelling case studies which exemplify effectiveness of root cause analyses in addressing customer complaints of Amgen drug products. The three customer complaints from three different drug products reported the following issues: pink discoloration in one drug product vial, cloudy liquid with suspended particles in another drug product vial, and brown discoloration in the third drug product vial. Consequently, a comprehensive root cause analyses were performed to identify and rectify the underlying issue, thereby mitigating the recurrence of complaints. The root cause analysis of the three events ruled out manufacturing processes as the source of contamination. Instead, it was more likely that the contamination originated at the healthcare providers' facilities. Orthogonal analytical test methodologies were employed on the samples to identify any potential contaminants. The cloudy appearance, pink and brown discolorations in the three customers returned vials were caused by non-Amgen products. The first vial had cyanocobalamin injectable (vitamin B12), the second vial had fosaprepitant (a non-Amgen drug), and the third vial had iron and saline solution (likely injectable anemia drug). A possible explanation for the three complaint samples is that they were mishandled during the process of administering the drug products at the facilities of the healthcare providers. Following the identification of the likely sources of contamination, Amgen followed standard compliant-handling procedures, which may include communicating results back to complaints or health providers as appropriate. In conclusion, the pursuit of root cause determination is paramount in addressing customer complaints and ensuring the quality, safety, and efficacy of biopharmaceutical products.
As global demand for biologics and advanced therapeutics accelerates, the transition from batch to continuous biomanufacturing has gained popularity as a strategy to meet the needs for scalability, flexibility, and cost-efficiency. In this work, we showcase how strategic collaboration between Cytiva and PAK BioSolutions enables rapid deployment of continuous downstream processing using commercially available technologies.Central to this approach is the connection and organization of the PAK Pilot system. This powerful orchestration platform streamlines the integration and automation of unit operations, including the ÄKTA pcc™ continuous chromatography system, which utilizes MabSelect PrismA™ resin for capture and Capto™ adhere resins for polishing, alongside the implementation of continuous low pH virus inactivation and virus filtration.We show how this collaboration unlocks the potential of Cytiva process intensification tools across the manufacturing process and leverages the PAK Pilot system to significantly reduce the time it takes to develop and operate an interconnected process. We also show aspects of the seamless control and simplification of continuous processing workflows with PAK Pilot system. These combined Cytiva and PAK BioSolutions technologies demonstrate a practical and scalable path to connected, continuous biomanufacturing, transforming what was once complex and time-consuming into a manageable and efficient reality.
This article provides comprehensive guidance on the safe handling, inactivation, and disposal of biohazardous waste generated in biomanufacturing processes. Effective waste treatment is a crucial element of biosafety management, as improper disposal of contaminated materials can pose serious risks to personnel, the environment, and surrounding communities. The document focuses on practical approaches and validation requirements for laboratories and production facilities working with Biosafety Level 1 and 2 (BSL-1/2) materials. The text highlights thermal inactivation as the most reliable and sustainable method for decontamination of both liquid and solid waste. Small liquid volumes can be sterilized using validated autoclave programs, whereas large volumes are treated in continuous-flow heat systems designed for energy efficiency and complete inactivation. Chemical inactivation serves as an alternative method, particularly for heat-resistant toxins such as saxitoxin or palytoxin. Solutions like sodium hypochlorite (NaOCl) or sodium hydroxide (NaOH) can effectively neutralize these substances, provided the reaction parameters are correctly set to the task and subsequent pH adjustments are validated to ensure environmental safety. Solid waste, including single-use components, filters, and contaminated materials, must be collected in leakproof containers, autoclaved, and disposed of as industrial waste. The document stresses the importance of autoclave validation, regular revalidation based on risk assessment, and technical safeguards such as exhaust air filtration or incineration to prevent the release of aerosols. Innovative solutions such as combined autoclave-shredder systems are introduced as highly efficient technologies that allow simultaneous shredding and sterilization, achieving up to 80% waste volume reduction and improving sterilization consistency. Overall, the article underscores a systematic, validated, and risk-based approach to biosafety waste treatment. It promotes the integration of technical precision, regulatory compliance, and sustainability to ensure that biohazardous materials are handled, inactivated, and disposed of safely within modern biomanufacturing environments.
The rising prevalence of Biologics and other sensitive therapeutics in clinical practice are rapidly modifying the landscape of subcutaneous (SC) drug delivery. Such route of administration empowers patients with the ability to self-administer at home, reducing the burden of frequent clinic visits and supporting the growing shift toward decentralized, patient-centric healthcare.Traditionally, SC injections have been limited to low volumes (typically ≤2 mL) due to concerns over pain, tissue tolerability, and absorption kinetics. However, emerging therapies-particularly monoclonal antibodies, anti-cancer treatments, and long-acting neurologic formulations-often require higher doses that cannot be feasibly delivered subcutaneously within these conventional volume constraints. Consequently, there is a growing demand for innovative solutions supporting self-administration of larger volumes, without compromising safety, therapeutic efficacy and compliance.Sensing such market pressure, Datwyler extended its range of NeoFlex™ plungers to complete larger containers, supporting the novel on-body injectors designed for slow, controlled delivery, expanding the feasible range of SC administration volumes. A collaborative and open approach among the parties involved with the development of the container closure system (CCS) and the device allows the optimization of pre-verified platform solutions, so to accelerate their time to market and, ultimately, availability to patients.
Detecting microorganisms in pharmaceutical water can be challenging. The current compendial method of plate counts is problematic. Organisms may not grow on the media that is used or may take longer than 7 days to appear on plates. As a result, the use of a bio-fluorescent particle counter (BFPC) offers advantages for the detection of water-borne organisms as their detection is not dependent on traditional culturing methods and is continuous and real-time.For this study, the ability of an online water bioburden analyzer (OWBA), a specific class of BFPC, is challenged to detect different organisms in pharmaceutical-grade water with an accuracy of 0.5 or greater AFU:CFU, variability less than 35% and linearity of r2>0.9025.Based on the results gathered, the OWBA can detect a wide range of organisms with accuracy, precision and linearity, indicating these microorganisms can swim, but they cannot hide!